Miro Sciences Ltd · ASX:MSX

Miro Sciences — Investor Presentation (November 2026)

18 slides from Miro Sciences's investor presentation, Nov 5, 2026

  1. Slide 1: Advancing Towards a New Treatment for Severe Crohn's Disease

    ASX:MSX al use only Formally NeuroScientific Biopharmaceuticals (ASX: NSB) StemSmart™ Advancing Towards a New 1 Treatment for Severe Crohn’s Disease November 2026 Miro Sciences Ltd ABN 13 102 832 995

  2. Slide 2: Disclaimer

    Disclaimer Presentation Information Forward Looking Statements This presentation has been prepared by Miro Sciences Ltd (ASX: MSX) based on information available to it as This presentation contains certain forward-looking statements that are based on the Company’s at the date of this presentation. T

  3. Slide 3: Company Snapshot

    Company Snapshot Corporate Share Information Capital Structure & Cash On Hand As at November 2026 ORDINARY SHARES PERFORMANCE SHARES OPTIONS al use only SHARE PRICE A$0.05 CAPITAL 389.72 million 1.50 million 43.25 million ~A$3.9 million MARKET CAPITALISATION ~A$19.5 million CASH (30/9/2026) ASX Anno

  4. Slide 4: Crohn's Disease: a Large Market in Need

    Crohn’s Disease: a Large Market in Need Large patient population, rising burden, limited durable treatment options al use only US$13B+ 6-8M ~30% Zero Global Crohn’s Patients with Crohn’s Do not respond to Approved treatment options 1,2 1,2 3 Disease market Disease globally standard therapies once st

  5. Slide 5: Crohn's Treatment Landscape & Where StemSmart Fits

    Crohn’s Treatment Landscape & Where StemSmart™ Fits Crohn’s alone is a ~US$13B+ market6 with unmet need for patients that fail biologics LINE OF THERAPY IN MODERATE–SEVERE CROHN’S LEADING CROHN’S DRUGS · 2025 SALES, US$B, ALL INDICATIONS4 al use only Conventional 1 Skyrizi IL-23 $17.6B +50% 5-ASA, s

  6. Slide 6: Proven Stem Cell Technology

    Proven Stem Cell Technology Strong market momentum for approved MSC products al use only Increased Sales for MSC Products Pathway to Commercialisation in US Mesoblast’s (ASX:MSB) recent market The United States FDA’s approval of Mesoblast’s announcement7 highlighted strengthened uptake MSC therapy8

  7. Slide 7: Introducing StemSmart

    Introducing StemSmart™ Purpose-built Mesenchymal Stem Cell (MSC) therapy for patients with limited options9 Designed for Hunts down inflammation sites and Activated MSC al use only severe inflammation modulate the immune response Optimised to enhance therapeutic activity Targets Developed for patients

  8. Slide 8: Prior Clinical Evidence: 80% Response in Refractory Patients

    Prior Clinical Evidence: 80% Response in Refractory Patients Two independent datasets in Crohn’s patients who had run out of approved treatment options al use only RESPONSE RATES IN CONTEXT12 PUBLISHED PHASE 2 · LUMINAL CROHN’S10 SPECIAL ACCESS PROGRAM · FISTULISING11 Clinical response (CDAI fall >1

  9. Slide 9: StemSmart Path to Phase 2 data

    StemSmart™ path to Phase 2 data Refractory Crohn’s Disease Phase 2 Program Achieved Upcoming TODAY · NOV 2026 al use only MAY 2026 Q3 2026 Q4 2026 Q1 2027 Q3/Q4 2027 Positive SAS results GMP engineering & Q4 2026 Phase 2 ethics (AU) Phase 2 first AU Phase 2 first US in fistulising Crohn’s demonstration

  10. Slide 10: Positive FDA Feedback Supports Phase 2 Development

    Positive FDA Feedback Supports Phase 2 Development A significant regulatory milestone supporting the proposed US clinical development pathway for StemSmart™.15 al use only Clinical trial design supported: US FDA agreement with the proposed Phase 2 trial design for refractory Crohn’s disease. Existing

  11. Slide 11: Building Manufacturing Readiness for Clinical Supply at Scale

    Building Manufacturing Readiness for Clinical Supply at Scale16,17 Large patient population, rising burden, limited durable treatment options al use only FOUR CRITICAL WORKSTREAMS 1 2 3 4 Manufacturing scale-up Technology transfer GMP & quality validation TGA licensing pathway Partner with Q-Gen to

  12. Slide 12: Phase 2 Trial Preparations Advancing Across Key Workstreams

    Phase 2 Trial Preparations Advancing Across Key Workstreams18 Clinical, operational & regulatory activities are progressing towards the planned initiation of the StemSmart™ Phase 2 al use only WORKSTREAM PROGRESS Clinical research organisation Southern Star Research appointed Clinical trial protocol

  13. Slide 13: Phase 2 Study Design: Randomised & Placebo-Controlled

    Phase 2 Study Design19: Randomised & Placebo-Controlled ~74 patients (target 66) with refractory Crohn’s disease, randomised 1:1 to StemSmart™ or placebo al use only SCREENING INDUCTION · 6 DOSES MAINTENANCE · 3 DOSES FOLLOW-UP KEY DESIGN FEATURES Patients Arm 1 · StemSmart™ MSC Aged ≥16; moderate–s

  14. Slide 14: A Clear Path from Phase 2 to Potential Commercialisation

    A Clear Path from Phase 2 to Potential Commercialisation Targeted clinical, regulatory and commercial milestones al use only TIMING DEFINITION OF SUCCESS Q4 2026 Australian Phase 2 trial initiated Q1 2027 First Australian patient treated Q2 2027 US IND submitted 2027 FDA Fast Track or RMAT designati

  15. Slide 15: Leadership & Advisory Strength

    Leadership & Advisory Strength20,21 Dr Marian Sturm Prof Catherine Cole Nathan Smith FFSc (RCPA), PhD, MSc, MBBS, FRACP, FRCPA Chris Knee BSc BComm BSc Hons Chief Medical Officer Chief Executive Officer Chief Scientific Officer 35 years in paediatric Chief Financial Officer al use only 25+ years in biolo

  16. Slide 16: Strong Global IP Position & Protection

    Strong Global IP Position & Protection Patented manufacturing process with freedom to operate Active Patents al use only “Cell Culture Method” for StemSmart™ technology – Dr Marian Sturm Granted in 14 Markets including Australia, USA, EU, Japan, UK, China, Canada, et al Patent expires in November 20

  17. Slide 17: Four Pillars Supporting the StemSmart Investment Opportunity

    Four Pillars Supporting the StemSmart™ Investment Opportunity Key Takeaways al use only 1 2 3 4 Strong Clinical Consistent Experienced Team Defined Development Foundation Operational Delivery & Partners Pathway Patented StemSmart™ Key clinical24, regulatory25 Established scientific, Clear clinical and

  18. Slide 18: Contact

    ASX:MSX al use only Formally NeuroScientific Biopharmaceuticals (ASX: NSB) Contact Nathan Smith Dr Anton Uvarov Chief Executive Officer Founding Non-Executive Director +61 477 738 404 +61 450 662 770 nsmith@miroscience.com au@mirosciences.com 18

Miro Sciences — Investor Presentation (November 2026) on 6ix